Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Date:8/21/2007

BOULDER, Colo. and MONTREAL, Aug. 21 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM), along with its collaborator MethylGene Inc. (TSX: MYG), today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States. Criteria for designation require that the product be intended for treatment of a condition affecting fewer than 200,000 people in the United States, and the application must include a rationale for the use of the drug in the rare disease or condition.

Preliminary data from a MGCD0103 Phase II monotherapy clinical trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of Clinical Oncology 2007 Annual Meeting in June and were included in the application for Orphan Drug Designation. The data demonstrated an objective complete response (CR) plus partial response (PR) rate of 40 percent and a disease control rate (CR + PR + stable disease for > 6 cycles) of 45 percent in a population of 20 evaluable patients that had relapsed disease or were refractory (unresponsive) to all previous treatments, including, in most cases, bone marrow transplantation. Fatigue and gastrointestinal side effects were the most common adverse events and dose modification was effective in many of these patients.

Orphan Drug Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include, tax credits, research and development grant funding, and reduced filing fees during development or at the time of application for marketing approval. Once approved, th
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... healthcare providers who have already immunized patients most ... virus may now offer the vaccine to anyone ... today. ,, Pennsylvania is expanding the H1N1 ... doses of vaccine have been allocated to healthcare ... priority groups. ,, "Many certified providers have already ...
(Date:12/15/2009)... LAKE ZURICH, Ill., Dec. 15 Fenwal ... improving blood collection, separation, safety and availability, announced ... has granted Fenwal approval to market InterSol ® ... InterSol ® solution is a specialized product ... donated platelets, a vital blood component used to ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 1New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 3New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 1Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 3Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 5Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 6Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 7Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 8Study shows how carbon nanotubes can affect lining of the lungs 10514 1Study shows how carbon nanotubes can affect lining of the lungs 10514 2
... total funding expected by year,s end, NEW ... pluripotent stem cell technology are among the cutting-edge,approaches ... J.,Fox Foundation,s Rapid Response Innovation Awards 2008. As ... a cure for PD, the,Foundation has awarded $1.1 ...
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
Other Medicine Technology:Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4
(Date:12/15/2009)... Food and Health Bureau has invited expressions of interest ... private hospitals at four sites in the Hong Kong ... March 31, 2010. ,, At a press conference, ... said the promotion of private hospital development was one ... Hong Kong government policy announced by Chief Executive Donald ...
(Date:12/15/2009)... -- Vitech Systems Group, a leading provider of ... announced today that it has completed a major ... Actors Guild-Producers Pension & Health Plans (SAG-PH). ,, ... to SAG-PH call center personnel in Burbank, Ventura ... Vitech,s V3 Benefits Administration System which consolidated data ...
(Date:12/15/2009)... and the CDC have released some sobering statistics concerning the parallel ... desks offer employers an effective means of combating this trend afflicting ... ... 2009 -- Rates of diabetes are climbing across America due in ... this rise the American Diabetes Association has stated that the rate ...
(Date:12/15/2009)... Team In Training (TNT), The Leukemia ... sports training program, has reached a remarkable milestone ... research and patient services. ,, For more than ... endurance sports training program, preparing amateurs and seasoned ... 100-mile century cycle ride or hike adventure. Through ...
(Date:12/15/2009)... Continuing Strike Force Operations Lead to Indictment of ... with more than $61 Million in Fraudulent Billing ... Thirty people have been charged in ... to submit more than $61 million in false ... of the Medicare Fraud Strike Force, Department of ...
Breaking Medicine News(10 mins):Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 2Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 5
... N.J., Nov. 26 Johnson & Johnson Pharmaceutical Research ... a Complete Response letter from the U.S. Food and ... for ceftobiprole for the treatment of complicated skin and ... , The FDA has ...
... Nov. 25 Nu Skin Enterprises, Inc.,(NYSE: NUS ... Day,presentation the morning of Thursday, Dec. 4, 2008, at the ... Skin Enterprises, executive management,team will discuss operational results and introduce ... event will be webcast and can be accessed by visiting ...
... than 20,000 people will,visit the emergency room due to the ... a odorless and colorless gas which will kill approximately,500 people ... Aurora Health Care and the American College ... this holiday season. The,winter months see a drastic increase of ...
... the rise,consumers are looking for ways to tighten their belts ... pets. In the midst of the downturn,veterinarians around the ... procedures. , Pet health ... a not-for-profit pet health resource - The Merck/Merial Manual for ...
... treatment choices, researchers say , , TUESDAY, Nov. 25 (HealthDay ... model for predicting the risk of recurrence in patients ... team at the Duke Institute for Genome Science & ... chemotherapy and targeted therapy regimens. , The researchers looked ...
... Cheng Wu, MD. MPH, Associate Professor and Assistant Director of ... Orleans School of Public Health, co-authored the Annual Report to ... in Lung Cancer, Tobacco Use, and Tobacco Control. The ... incidence and death rates, as well as wide variations in ...
Other Medicine News:Health News:FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections 2Health News:FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections 3Health News:'Tis the Season for Carbon Monoxide 2Health News:As Consumers Put a Leash on Spending, Experts Caution Against Being 'Penny Wise and Pound Foolish' with Their Pets 2Health News:As Consumers Put a Leash on Spending, Experts Caution Against Being 'Penny Wise and Pound Foolish' with Their Pets 3Health News:As Consumers Put a Leash on Spending, Experts Caution Against Being 'Penny Wise and Pound Foolish' with Their Pets 4Health News:Gene Test Could Predict Colon Cancer's Return 2Health News:LSUHSC's Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer 2Health News:LSUHSC's Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: